Both options are 99% effective in preventing HIV if taken daily. The second option, approved in 2019, is a combination of emtricitabine and a different prodrug, tenofovir alafenamide-this combination is called Descovy ® or F/TAF. The first option, approved in 2012, is a combination of two drugs called emtricitabine/tenofovir disoproxil fumarate-also known as Truvada ® or F/TDF. There are currently two approved options for PrEP in the US both are oral medications. Pre-exposure prophylaxis (or PrEP) prevents HIV acquisition in individuals at risk of HIV infection. While the approval of F/TAF is the first step in personalization of PrEP, additional options are still warranted to help accommodate the wide spectrum of individuals at risk of HIV with different lifestyles, medical histories, preferences, and requirements.īone Decision making HIV prevention Kidney Personalized medicine Pre-exposure prophylaxis Preference Renal Tenofovir alafenamide Tenofovir disoproxil fumarate. F/TAF may be the preferred medication for cisgender men and transgender women at risk of HIV infection who are predisposed to, or already have, bone or renal conditions. We identified that the introduction of F/TAF provides a valuable alternative to F/TDF, allowing the personalization of PrEP. We reviewed the safety profiles of F/TDF and F/TAF to develop an evidence-based algorithm for selecting the appropriate PrEP medication, based on biological, behavioral, and health characteristics of an individual at risk of HIV, and considered how the choice of PrEP medication may or may not compound safety concerns for these individuals. In this narrative review, we conducted a comprehensive evaluation of the populations at risk of HIV who may also be affected by, or at risk of, bone or renal conditions. While both medications have been found to be efficacious and well tolerated, several studies have identified that important differences exist with regards to pharmacokinetics, bone and renal safety profiles, and other factors.
An ongoing randomized, double-blind, Phase 3 study (DISCOVER) demonstrated that F/TAF had non-inferior efficacy to F/TDF. Two PrEP medications are currently approved: emtricitabine/tenofovir disoproxil fumarate (Truvada ® F/TDF) was approved by the US Food and Drug Administration in 2012, followed by emtricitabine/tenofovir alafenamide (Descovy ® F/TAF) in 2019. (Information in Universal Coverage provided by AHS, 2018).Pre-exposure prophylaxis (PrEP) medication is a key component of the HIV prevention strategy in the US, which has been demonstrated to be highly effective in preventing HIV acquisition among individuals at risk. Individuals who inject drugs and share injection supplies.Heterosexual persons who engage in sex with partner(s) who may be from a population or community with high rates of HIV.Heterosexual persons in an ongoing relationship with a partner who is HIV positive who is not taking treatment, has HIV virus in their blood.Sex partner(s) known to be living with HIV who are not taking treatment, have HIV virus in their blood, or don't know their virus levels.Chlamydia, gonorrhea or syphilis infection in the past 12 months.Men who have sex with men (MSM), transwomen, gender-diverse individuals who report having anal sex in the past 6 months without using a condom, in addition to reporting any of the following:.To access universal coverage in Alberta, you must have an Alberta Health Care Card and meet the following eligibility criteria: 1, 2018, the Government of Alberta has made generic versions of PrEP available at no cost to individuals who are at high risk of HIV acquisition.
0 kommentar(er)
